Showing results (61-70 of 149) with videos related to

Sort By:
Pageof 15
Future Oncology (London, England)|October 21, 2022
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancerHope S Rugo, Javier Cortes, Carlos H Barrios, et al.
Breast Cancer Research and Treatment|November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltrationMargarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
NPJ Breast Cancer|April 14, 2023
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrenceFrederick M Howard, James Dolezal, Sara Kochanny, et al.
Breast Cancer Research and Treatment|February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancerNan Chen, Margarite Matossian, Poornima Saha, et al.
Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Nature Communications|July 21, 2021
The impact of site-specific digital histology signatures on deep learning model accuracy and biasFrederick M Howard, James Dolezal, Sara Kochanny, et al.
JAMA Network Open|March 30, 2023
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast CancerFangyuan Zhao, Minoru Miyashita, Masaya Hattori, et al.
Annals of Surgical Oncology|July 26, 2014
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017Kandace P McGuire, E Shelley Hwang, Alan Cantor, et al.
Breast Cancer Research and Treatment|August 8, 2025
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancerErica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, et al.
Cancer|December 26, 2023
Validation of the RSClin risk calculator in the National Cancer Data BaseAugustin G L Vannier, Asim Dhungana, Fangyuan Zhao, et al.
Pageof 15